P1, N=4, Terminated, Celgene | N=156 --> 4 | Active, not recruiting --> Terminated; Business objectives have changed

P2, N=20, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

P2, N=48, Recruiting, ETOP IBCSG Partners Foundation | Not yet recruiting --> Recruiting | N=30 --> 48

Patients received cibisatamab with escalating doses of FAP-4-1BBL weekly or every 3 weeks after obinutuzumab pretreatment to mitigate anti-drug antibody formation. These findings demonstrate the feasibility of combining tumor antigen-directed T cell engagement with localized co-stimulation, with evidence of immune activation and preliminary antitumor activity supporting further clinical development. ClinicalTrials.gov identifier: NCT04826003 .

Treatment-emergent adverse events (TEAEs) led to treatment discontinuation in 16.0% of patients with CR; the most common TEAE was cytokine release syndrome (56.4%). This generally manageable safety profile and the sustainability of CRs support odronextamab as a potential long-term treatment for heavily pretreated R/R FL.

She was treated with tarlatamab, achieving 4 months of treatment response with symptomatic relief and improved performance status. This case represents the first documented evidence of the clinical benefit of tarlatamab in transformed SCLC and highlights its therapeutic potential in this challenging setting.

P1/2, N=26, Not yet recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P2 --> P1/2 | Initiation date: Mar 2026 --> Jun 2026

P1/2, N=10, Not yet recruiting, Tang-Du Hospital

P3, N=670, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting

The recent approval of the DLL3×CD3 bispecific T-cell engager tarlatamab represents one of the first meaningful advances in relapsed small cell lung cancer (SCLC) in decades, yet responses remain heterogeneous and resistance is inevitable...These findings underscore the clinical relevance of TF-defined molecular subtypes in human SCLC. More broadly, they highlight the power of integrating longitudinal in vivo plasma transcriptional profiling from patient plasma with functional mouse modeling to uncover clinical and biological mechanisms of response and resistance to cell-surface-targeted therapies.

P1, N=30, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting

P1, N=48, Not yet recruiting, Shanghai Henlius Biotech